Sign up USA
Proactive Investors - Run By Investors For Investors
Why invest in VXL?
Vaxil: THE INVESTMENT CASE

Vaxil at the vanguard of immuno-oncology

The company is developing ImMucin, which targets MUC-1, a unique cancer antigen with high specificity to malignant cells, and results in a potent stimulation effect on T and B cells.
Vaxil at the vanguard of immuno-oncology
INVESTMENT OVERVIEW: VXL The Big Picture
Vaxil in the spotlight with good investment prospects

Immuno-oncology is a type of cancer treatment designed to boost the body's natural defences to fight the disease.

It uses substances either made by the body or in a laboratory to improve or restore immune system function.

Immunotherapy in cancer treatment could every bit as significant as the breakthroughs made in HIV/AIDS and Hepatitis around 15 years ago, according to the specialist research firm BioNap.

“For biotech investors, the prospect of curing cancer has led to an abundance of opportunities as more and more companies enter the space,” it said in a note published this week.

Interest in this emerging area is such that an exchange-traded fund dedicated to cancer immunotherapy has been set up that invests in a spread of companies in this sector.

It is called the Series Solutions Trust Loncar Cancer Immunotherapy ETF (NASDAQ:CNCR).

One company at the vanguard of immuno-oncology is Ontario-based Vaxil Bio Ltd (CVE:VXL).

Read Vaxil gets US Patent and Trademark nod for Immunotherapy tech

It is developing ImMucin, which targets MUC-1, a unique cancer antigen with high specificity to malignant cells, and results in a potent stimulation effect on T and B cells.

In fact, MUC1 antigen is a well-known cancer marker present in 90% of all cancers.

ImMucin was recently shown to work in combination with leading checkpoint inhibitors, such as anti-PD1 and anti-CTLA-4 antibodies, inhibiting the spread of tumours in bone marrow and blood samples derived from multiple myeloma patients.

Combination therapies of this kind are increasingly seen as the way ahead given the complexities associated with the disease and the diverse responses humans have to the current crop of drugs.

Vaxil features in new research report

Vaxil has just been featured as a stock to watch in a research note from BioNap.

“ImMucin, and its derived antibodies could ultimately serve as starting materials for the development of specific T cell therapies such as CAR-T and allogeneic T cell transplantation,” said BioNap.

 “Since the safety of ImMucin has proven excellent and it has the capacity to work across immunologic barriers, it appears to be a natural candidate to combine with these modalities and others.”

Those, like Vaxil, exploring immunotherapy cancer combat may also be recipients of financial aid from the $1.8bn earmarked for outgoing President Barack Obama’s national “Moonshot” initiative to eliminate cancer, unveiled at the last State of the Union speech in January 2016.

Read Vaxil Bio encouraged by cancer drug progress on two fronts

Vaxil’s drug, meanwhile, has received Orphan Drug Designation in the US and Europe and completed a successful Phase-I/II trial.

This should shorten the time it takes to get the treatment out onto the market if it successfully navigates the R&D phase.

The company has also branched outside of North America, to work with other leading institutions around the world.

Read Vaxil collaborates with Israel’s Hadassah Medical Center

 

View full VXL profile View Profile

Vaxil Timeline

Related Articles

picture of drug researcher
July 19 2017
Enlarged company can become an emerging leader in the application of gene modulation technologies
"Cancer" in bold
10:45
Undoubtedly the highlight was the successful completion of US and European studies evaluating over 400 patients using the company’s Parsortix system
picture of drug research
June 05 2017
With US licensee driving the Phase 1 trials of Sareum's lead candidate, SRA737, the focus moves to TYK2, a compound that is targeting psoriasis, rheumatoid arthritis, and other autoimmune disorders
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use